16 June 2017
Dr. Jack Edwards receives the Rhoda Benham Award from Medical Mycology Society
LOS ANGELES – (June 8, 2017) – The Medical Mycology Society of the Americas has honored John E. “Jack” Edwards, Jr., MD, an LA BioMed lead researcher, as the winner of the 2017 Rhoda Benham Award. The award is given “to an individual from the Americas for continuous outstanding or meritorious contributions to medical mycology,” which is the study of fungal diseases.
“Congratulations to Dr. Edwards for this important recognition of his many accomplishments and contributions to this field of scientific study,” said David I. Meyer, PhD, LA BioMed president and CEO. “For more than three decades, Dr. Edwards has been dedicated to tackling deadly infectious and fungal diseases, providing the leadership at LA BioMed and in the larger scientific community on critical research that holds great promise for effective vaccines and therapies.”
Dr. Edwards' research focuses on understanding the cellular and molecular mechanisms of antimicrobial host defense, principally those caused by the fungus Candida, one of the most common causes of life-threatening blood infections in hospitalized patients. With his work he hopes to dramatically advance the development of new anti-fungal agents and immunotherapies to prevent and treat life-threatening infections.
Dr. Edwards, together with his group of colleagues, founded NovaDigm Therapeutics to translate the three decades of research into products that will prevent or treat serious infectious diseases. NovaDigm is developing innovative immunotherapeutics and vaccines to protect patients from fungal and bacterial disease, which can be recurrent, drug-resistant and in many cases, life-threatening. NovaDigm’s lead development candidate, NDV-3A, is the first vaccine to demonstrate efficacy for an opportunistic fungus in an exploratory, placebo controlled trial.
In addition, Dr. Edwards has served as a focal member of the National Institutes of Health Mycoses Study Group, overseeing numerous clinical trials in antifungal strategies. He’s received several honors for his work, including recognition as an LA BioMed Legend.
He has served on several prestigious panels, including as chairman of the Board of Scientific Counselors of the Clinical Center at the National Institutes of Health. He is the former acting chairman of the Anti-Infective Advisory Committee of the Food and Drug Administration. He has also served as an elected counselor for the International Immunocompromised Host Society and the Infectious Disease Society of America (IDSA) as well as a member of the IDSA Antimicrobial Availability Task Force.
In addition to his work at LA BioMed, Dr. Edwards is an emeritus distinguished professor of medicine at the David Geffen School of Medicine at UCLA and a former chief of the Division of Infectious Disease at Harbor-UCLA Medical Center.
Founded in 1952, LA BioMed is one of the country's leading nonprofit independent biomedical research institutes. It has approximately 100 principal researchers conducting studies into improved treatments and therapies for cancer, inherited diseases, infectious diseases, illnesses caused by environmental factors and more. It educates young scientists and provides community services, including prenatal counseling and childhood nutrition programs. LA BioMed is academically affiliated with the David Geffen School of Medicine at UCLA and located on the campus of Harbor-UCLA Medical Center.
LA BioMed's technologies have helped to generate numerous global medical breakthroughs, including the invention of the modern cholesterol test, the conception and development of the modern-day U.S. paramedic model of emergency patient care, the first isolation and administration of a lung surfactant to treat premature babies, the FDA-approved drug Kybella® for submental fullness, the FDA-approved drug Aldurazyme® for a Mucopolysaccharidosis, the development of low-cost antiseptic eye drops that prevented blindness in hundreds of thousands of newborns in developing countries and an effective treatment for Sickle Cell disease.Print
NovaMedica to localize in Russia one of the most popular anti-migraine drugs in the world
21 March 2023
Merry Christmas and Happy New Year!
27 December 2022
NovaMedica registers two own-development CNS products, one without equivalents in Russia and the other – in the world
15 December 2022
In April 2023 drugs worth of 54.3 billion rubles were produced in Russia
09 June 2023
In Russia, child mortality is declining, while life expectancy is growing
09 June 2023
How can biopharma strengthen its resilience?
08 June 2023
Sergey Glagolev: Foreign companies are interested in conducting clinical trials in Russia
08 June 2023